This is a StreetInsider.com Premium Only Page

(KZR) – StreetInsider.com Reports

Mar 14, 2024 04:04 PM Kezar Life Sciences, Inc. (KZR) Misses Q4 EPS by 6c

Feb 26, 2024 06:11 PM Kezar Life Sciences (KZR) and Everest Medicines Announce IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Nov 14, 2023 07:09 AM Kezer Life Sciences (KZR) PT Lowered to $2 at Wells Fargo

Nov 14, 2023 04:01 AM Kezar Life Sciences, Inc. (KZR) Tops Q3 EPS by 4c

Oct 4, 2023 04:33 PM Jones Trading Downgrades Kezer Life Sciences (KZR) to Hold

Oct 3, 2023 04:11 PM Kezar Life Sciences (KZR) Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as CEO

Oct 3, 2023 04:05 PM Kezar Life Sciences (KZR) Halted, News Pending

Sep 25, 2023 06:34 AM Kezer Life Sciences (KZR) PT Raised to $20 at H.C. Wainwright

Sep 20, 2023 07:37 PM Kezar Life Sciences (KZR) and Everest Medicines Enter Deal to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asi

Aug 11, 2023 06:57 AM Kezer Life Sciences (KZR) PT Lowered to $18 at H.C. Wainwright

Aug 11, 2023 03:45 AM Wells Fargo Downgrades Kezer Life Sciences (KZR) to Equal Weight

Aug 10, 2023 04:20 PM Kezar Life Sciences, Inc. (KZR) Misses Q2 EPS by 2c

Aug 10, 2023 04:06 PM Kezar Life Sciences, Inc. (KZR) Misses Q2 EPS by 2c

May 12, 2023 07:15 AM Kezer Life Sciences (KZR) PT Lowered to $13 at Wells Fargo

May 11, 2023 05:40 PM Kezar Life Sciences, Inc. (KZR) Misses Q1 EPS by 2c

Mar 16, 2023 06:14 AM William Blair Downgrades Kezer Life Sciences (KZR) to Market Perform

Jan 3, 2023 07:24 AM Kezer Life Sciences (KZR) PT Lowered to $14 at Wells Fargo

Nov 14, 2022 07:00 AM Kezar Life Sciences (KZR) Presents Positive Complete Results from the MISSION Phase 2 Trial of Zetomipzomib

Nov 10, 2022 05:17 PM Kezar Life Sciences, Inc. (KZR) Tops Q3 EPS by 5c

Nov 3, 2022 10:02 AM Kezar Life Sciences (KZR) Reports Positive Complete Results from the MISSION Phase 2 Trial of Zetomipzomib

Oct 3, 2022 04:01 PM Kezar Life Sciences (KZR) Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

Jun 28, 2022 09:39 AM Increasing unusual option volume: KZR ENDP AVPT WPC BOXD

Jun 28, 2022 09:11 AM Pre-Open Stock Movers 06/28: Spirit Gains on Revised Bid; Nike Falls Following Results (more...)

Jun 28, 2022 08:56 AM Kezer Life Sciences (KZR) Reports Positive Phase 2 Data, Jefferies Sees Registrational Path

Jun 28, 2022 04:59 AM Kezer Life Sciences (KZR) PT Raised to $17 at Wells Fargo

Jun 27, 2022 06:01 PM After-Hours Stock Movers 06/27: Morgan Stanley, Goldman Gain on Dividend Hike News Post Stress Tests (more...)

Jun 27, 2022 04:11 PM Kezar Life Sciences (KZR) Climbs 35% Following Positive Results from Phase 2 Trial Evaluating Zetomipzomib for Treatment of Patients with LN

Jun 27, 2022 04:02 PM Kezar Life Sciences (KZR) Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis

May 13, 2022 06:45 AM Kezer Life Sciences (KZR) PT Lowered to $13 at Wells Fargo

May 4, 2022 08:03 AM Kezer Life Sciences (KZR) PT Lowered to $21 at Jefferies

May 3, 2022 04:01 PM Kezar Life Sciences (KZR) Reports Topline Results from PRESIDIO Trial of Zetomipzomib

Dec 20, 2021 05:05 PM Kezar Life Sciences (KZR) Files $200M Mixed Shelf

Dec 10, 2021 07:02 AM Kezar Life Sciences (KZR) Appoints Courtney Wallace to its Board

Dec 7, 2021 04:39 PM Wells Fargo Starts Kezer Life Sciences (KZR) at Overweight

Nov 16, 2021 09:20 AM Pre-Open Stock Movers 11/16: (KZR) (AXON) (RMO) Higher; (BODY) (OPTN) (CLOV) Lower (more...)

Nov 15, 2021 04:48 PM Kezar Life Sciences (KZR) Climbs 47% Following Interim Results from the MISSION Phase 2 Trial

Nov 15, 2021 04:07 PM Kezar Life Sciences (KZR) Reports Interim Results from the MISSION Phase 2 Trial

Aug 23, 2021 07:03 AM Kezar Life Sciences (KZR) Completes Enrollment of Its Phase 2 PRESIDIO Trial of KZR-616

Jul 20, 2021 06:59 AM Jones Trading Starts Kezer Life Sciences (KZR) at Buy

Jun 1, 2021 04:05 PM Kezar Life Sciences (KZR) Appoints Micki Klearman, Rheumatology Industry Expert to its Board

Mar 25, 2021 08:27 AM Jefferies Reiterates Buy Rating on Kezer Life Sciences (KZR) Ahead of '616 PhII Lupus Nephritis Data

Dec 14, 2020 04:02 PM Kezar Life Sciences (KZR) Added to the Nasdaq Biotechnology Index

Oct 23, 2020 07:04 AM Kezar Life Sciences (KZR) Granted Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis & Dermatomyositis

Sep 18, 2020 09:29 AM Pre-Open Movers 09/18: (WPRT) (SAVA) (PIC) Higher; (CKPT) (ADMP) (BYND) Lower (more...)

Sep 17, 2020 05:57 PM After-Hours Movers 09/17: (KZR) (PLAY) Higher; (ADMP) (EPRT) Lower (more...)

Jun 8, 2020 06:01 AM Kezar Life Sciences (KZR) Announces Proposed Common Share Offering

Jun 3, 2020 05:36 PM Kezar Life Sciences (KZR) Provides Data Update from MISSION Study of KZR-616 in Patients with SLE

Apr 9, 2020 07:08 AM Kezar Life Sciences (KZR) anticipates delays in clinical development and data release milestones for KZR-616 due to pandemic

Jan 31, 2020 09:24 AM Pre-Open Stock 01/31: (NAV) (NNVC) (AMZN) Higher (WWE) (KZR) (BZH) Lower (more...)

Jan 31, 2020 08:13 AM Kezar Life Sciences (KZR) Prices $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants